Potential Role of Monocyte Chemotactic Protein 1 (MCP-1) in the Breast Cancer...Marion Hartmann
MCP-1 has a potentially important role in the breast tumour microenvironment.
The results presented suggest it may exert its effect by promotion of tumour cell survival through up-regulation of anti-apoptotic factors and pro-migratory factors and thus may be a target for therapeutic intervention.
Gene expression signature of primary breast tumour stromal cellsMarion Hartmann
Tumour stromal cells secrete proangiogenic and prometastatic factors, such as MMP3 and may support breast cancer progression through promotion of tumour angiogenesis and invasion
Cellular Signaling Pathways have direct implications on our understanding of tumor cell behavior. A general overview is presented here followed by a brief discussion of some of the major pathways currently implicated in cancer progression : Ras/RAF/MAP kinase pathway and PI3K/AKT/mTOR pathway s
Potential Role of Monocyte Chemotactic Protein 1 (MCP-1) in the Breast Cancer...Marion Hartmann
MCP-1 has a potentially important role in the breast tumour microenvironment.
The results presented suggest it may exert its effect by promotion of tumour cell survival through up-regulation of anti-apoptotic factors and pro-migratory factors and thus may be a target for therapeutic intervention.
Gene expression signature of primary breast tumour stromal cellsMarion Hartmann
Tumour stromal cells secrete proangiogenic and prometastatic factors, such as MMP3 and may support breast cancer progression through promotion of tumour angiogenesis and invasion
Cellular Signaling Pathways have direct implications on our understanding of tumor cell behavior. A general overview is presented here followed by a brief discussion of some of the major pathways currently implicated in cancer progression : Ras/RAF/MAP kinase pathway and PI3K/AKT/mTOR pathway s
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyTuhin Samanta
Illusory Antigen Receptor (CAR) T-cell treatment includes hereditary alteration of patient's autologous T-cells to express a CAR explicit for a tumor antigen, following by ex vivo cell extension and re-imbuement back to the patient. Vehicles are combination proteins of a chose single-chain section variable from a particular monoclonal immune response and at least one T-cell receptor intracellular flagging spaces. This T-cell hereditary change may happen either by means of viral-based quality exchange strategies or nonviral techniques, for example, DNA-based transposons, CRISPR/Cas9 innovation or direct exchange of in vitro deciphered mRNA by electroporation.
Contains the speakers details of the 23rd International Conference on Cancer Research and Pharmacology.
For more details, visit: https://cancer.cmesociety.com/
This PPT is about immune system and immune therapy, some basic knowledge about Chimeric Antigen Receptor or CAR technology and its application on tumor therapy.
Welcome to watch Creative Biolabs’ slide about immune system and immune therapy. here we share some basic knowledge about T Cell Receptor Engineered T Cell Technology or TCR-T and its application on tumor therapy.
A treatment used to help the immune system fight diseases, such as cancer and infections with certain viruses. These T cells are given back to the patient to help the immune system fight disease" Also called cellular adoptive immunotherapy".
Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...Thermo Fisher Scientific
Tumor mutation load predicts durable benefit from immune checkpoint inhibitors in several cancer types. Existing methods to estimate tumor mutation load have large input DNA and extensive infrastructure requirements and are associated with delays due to shipping biopsy samples to central laboratories. We demonstrate the ability of a targeted panel with fast
turn-around time and low input requirement for estimating mutation load from tumor samples to advance research in immuno-oncology.
Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising approach, which has shown remarkable ability to eliminate various kinds of tumors, especially for B cell malignancies, with up to 95% response rates and durable complete remission. A CAR mainly consists of a single chain variable fragment (scFv) from a monoclonal antibody which binds a specific antigen, a hinge and spacer element, a trans-membrane region and an internal signaling domain such as CD3ζ.
A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is being studied in the treatment of some types of cancer. Also called chimeric antigen receptor T-cell therapy.
It is early days, but the engineered expression of chimeric antigen receptors (CARs) on the surface of T cells the redirection of T‑cell specificitymay lead to improvements in clinical outcomes for patients with solid tumors.
The biology of neuroendocrine tumors remains poorly understood. Thanks to the United Kingdom & Ireland Neuro-Endocrine Tumor Society for inviting me to overview current knowledges during its yearly meeting. Enclosed, please find attached the slides that were used for this lecture. I hope this will generate insights for pushing forward the discovery of novel targets and biomarkers.
CEL-SCI Corporation Presents First-of-its-Kind Results For Lower-Risk Advanced Primary SCCHN Population in 25+ Years Through Its Phase III IT-MATTERS Study
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyTuhin Samanta
Illusory Antigen Receptor (CAR) T-cell treatment includes hereditary alteration of patient's autologous T-cells to express a CAR explicit for a tumor antigen, following by ex vivo cell extension and re-imbuement back to the patient. Vehicles are combination proteins of a chose single-chain section variable from a particular monoclonal immune response and at least one T-cell receptor intracellular flagging spaces. This T-cell hereditary change may happen either by means of viral-based quality exchange strategies or nonviral techniques, for example, DNA-based transposons, CRISPR/Cas9 innovation or direct exchange of in vitro deciphered mRNA by electroporation.
Contains the speakers details of the 23rd International Conference on Cancer Research and Pharmacology.
For more details, visit: https://cancer.cmesociety.com/
This PPT is about immune system and immune therapy, some basic knowledge about Chimeric Antigen Receptor or CAR technology and its application on tumor therapy.
Welcome to watch Creative Biolabs’ slide about immune system and immune therapy. here we share some basic knowledge about T Cell Receptor Engineered T Cell Technology or TCR-T and its application on tumor therapy.
A treatment used to help the immune system fight diseases, such as cancer and infections with certain viruses. These T cells are given back to the patient to help the immune system fight disease" Also called cellular adoptive immunotherapy".
Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...Thermo Fisher Scientific
Tumor mutation load predicts durable benefit from immune checkpoint inhibitors in several cancer types. Existing methods to estimate tumor mutation load have large input DNA and extensive infrastructure requirements and are associated with delays due to shipping biopsy samples to central laboratories. We demonstrate the ability of a targeted panel with fast
turn-around time and low input requirement for estimating mutation load from tumor samples to advance research in immuno-oncology.
Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising approach, which has shown remarkable ability to eliminate various kinds of tumors, especially for B cell malignancies, with up to 95% response rates and durable complete remission. A CAR mainly consists of a single chain variable fragment (scFv) from a monoclonal antibody which binds a specific antigen, a hinge and spacer element, a trans-membrane region and an internal signaling domain such as CD3ζ.
A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is being studied in the treatment of some types of cancer. Also called chimeric antigen receptor T-cell therapy.
It is early days, but the engineered expression of chimeric antigen receptors (CARs) on the surface of T cells the redirection of T‑cell specificitymay lead to improvements in clinical outcomes for patients with solid tumors.
The biology of neuroendocrine tumors remains poorly understood. Thanks to the United Kingdom & Ireland Neuro-Endocrine Tumor Society for inviting me to overview current knowledges during its yearly meeting. Enclosed, please find attached the slides that were used for this lecture. I hope this will generate insights for pushing forward the discovery of novel targets and biomarkers.
CEL-SCI Corporation Presents First-of-its-Kind Results For Lower-Risk Advanced Primary SCCHN Population in 25+ Years Through Its Phase III IT-MATTERS Study
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Laura Berry
Presented at the 4th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit: www.global-engage.com
Greg Kuehn, President and COO of Metabiomics, presents the MB-01 colorectal adenoma clinical research study, sequencing technology and microbiome diagnostics platform.
Development of a new venture pioneering medical screening tests for a number of diseases simply though breath samples. This technology is changing the way people check on their health and will save millions of lives through the early detection of Lung cancer alone.
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...CrimsonpublishersCancer
Cancer treatments have traditionally entailed system wide toxicity with debilitating side effects for the patient. The demand for targeted therapies is clearly exhibited in the pipeline of large pharmaceuticals where the need to identify delivery vehicles that offer the prospects of more targeted, efficacious treatments with fewer side effects is paramount. Historically a number of technologies have been tried and tested including antibody drug conjugates, nanoparticles, cell surface markers and targeting the tumor microenvironment. Unfortunately, these approaches have often had lackluster results and created alternative toxic profiles, such as immune activation. Interest in an historic technology, cell penetrating peptides (CPPs), has been recently reinvigorated, presenting the opportunity to deliver targeted, biologically active cargoes to cancerous cells for treatment without systemic side effects.
Management of MSI High Solid Tumors and the impact of adding Immunotherapy upon improving survival outcome and response rate. Colorectal and Non Colorectal tumors.
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:
Introduction to Lung Cancer Vaccine
Global Lung Cancer Vaccine Market Analysis
Global Lung Cancer Vaccine Pipeline by Company & Phase
Global Lung Cancer Vaccine Pipeline: 29 Vaccines
Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C™ & Vaxira®)
Personalized Cancer Vaccines: Progress & Possibilities
Lung Cancer Vaccine Mechanism
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessFitking Fitness
"Feature:
• Intelligent Ergonomically Design Glute Builder Is A Must Have For Those Looking To Target Their Gluteal Muscles And Hamstrings With Precision.
• The Ability To Adjust The Starting Position, This Machine Allows For A More Targeted Workout That Is Tailored To Your Specific Needs.
• Spacious And Supportive Cushioned Seat Provide Added Comfort And Stability During Your Workout."
Get more information visit on:- www.fitking.in
Our mail I.D:-care@fitking.in, fitking.in@gmail.com
Call us at :- 9958880790, 9870336406, 8800695917
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
Rate Controlled Drug Delivery Systems, Activation Modulated Drug Delivery Systems, Mechanically activated, pH activated, Enzyme activated, Osmotic activated Drug Delivery Systems, Feedback regulated Drug Delivery Systems systems are discussed here.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
2. 2
Overview
1 in 3 will get cancer – many will not survive
***
Our mission
develop groundbreaking new treatments for those
suffering with cancer
3. 3
Business Model
DISC TARGET HITS LEAD
PRE-
CLIN
IND PHASE 1 PHASE 2 PHASE 3 APP LAUNCH
LEAD
IND
PACKAGE
EARLY
CLINICAL
PRE-
CLINICAL
10-15 YEAR DEVELOPMENT
Value Inflection:
LICENSE IN PARTNER/
EXIT/IPO
4 – 5 YEAR DEVELOPMENT
4. 4
Phase I Value Creation Potential
Phase I
Oncology
Exits
$100m -
>$300m
5. 5 Spanish National Cancer Research Centre
Collaboration with CNIO - June 2013
6. Comprising first-in-class agents protected by composition
of matter patents
6
Pipeline – Targeted Therapeutics
RESEARCH PRE-CLIN IND PHASE ITARGET
MULTIPLE MYELOMA
NSCLC
IBL-202 (PIM/PI3K)
IBL-300s (PIM/PI3K/mTOR)
HAEM MALIGNANCIESIBL-100s (Pan-PIM)
OTHER K-RAS TUMOURS
B-CELL LYMPHOMAS
B-CELL LYMPHOMAS
Secure Partner after
Phase I
Secure Partner at IND
7. 7
PIM Kinase a driver of resistance in AKT/PI3K
1. PIM expression dramatically
elevated by PI3K/AKT pathway
inhibition
2. PIM mediates feedback loop
driving acquired resistance to a
number of treatment modalities.
Underpins rationale for co-
targeting PI3K and PIM;
huge clinical opportunity
8. 8
IBL-300s – Targeting Molecular Subsets in NSCLC(Stage IV)
EGFR TKI ResistantMutant K-RasDe novo PI3k activation
Lung cancer leading cause of cancer death (1.6m ww)
- NSCLC ~80% = $10bn market by 2020
Role for PI3K and PIM co-targeting in NSCLC Rationale for IBL-300s
NSCLC - K-Ras mutated
in 15-30%
Downstream activation
include
PI3K/AKT/mTOR
PIM inhibition shuts
down growth in mutant
K-Ras NSCLC cell lines
NSCLC - EGFR
mutations in ~10% de
novo
Cancer recurs (~12mo)
with ~10% due to PI3K
activation
PIM elevated in EGFR
TKI resistant lines
Squamous cc – PIK3CA/
PTEN mutations ~30%
PIM and PI3K inhibitors
act synergistically in vitro
and in vivo
PIM mediates PI3K/AKT
resistance
9. 9
Research Collaboration Network
Network spanning US, EU, Australia
NSCLC, pancreatic, ovarian, multiple myeloma, DLBCL,
MCL, CLL, neuroblastoma, breast cancer, mechanistic
10. Leadership
Darren
Cunningham
CEO
15 year record
in licensing,
M&A, IP,
fundraising, IR
Amarin, Elan,
PWC
B. Comm, M.
Acc, FCA
Dr. Michael
O’Neill
Director R&D
22 year drug
discovery and
development
Eli Lilly,
Almirall, Merck
BA
Psychology,
PhD
MANAGEMENT ONCOLOGY ADVISORY PANEL
Prof. Josep
Tabernero
Director, Vall
d’Hebron Institute of
Oncology
Led clinical
development of
PI3K pathway
inhibitors
ESMO Executive
Board
Prof. Funda
Meric-Bernstam
Professor of
Surgical Oncology;
and
Chair Department
of Investigational
Cancer
Therapeutics, M.
D. Anderson
Cancer Center
Dr. Martin Page
30+ years
experience in
oncology R&D
Previous VP, Global
Head of Oncology
Res. J&J
Roles with OSI
Pharma, Oxford
Glycosciences, and
Glaxo-Wellcome
11. Incorporated 2012
Headquartered in Dublin, with base in London
2 full time employees
– Internship program, 3 in 2015
– PhD in TCD via Innovation Partnership
6 board members; panel of international scientific
advisors
6 CROs (UK, France, China, India)
>10 research collaborations (US, Ireland, UK,
Germany, Sweden, Australia)
~€2.2m raised to date (EI, VC and privates)
11
Corporate profile